P-041 CLINICAL FEATURES ASSOCIATED WITH COGNITIVE IMPAIRMENT IN CHINESE PARKINSON’S DISEASE PATIENTS: A CROSS-SECTIONAL STUDY J. Du, S. Cui, S. Chen. Department of Neurology, Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China Objective: Cognitive impairment is prevalent in Parkinson’s disease (PD) that contributes to the life bur- den, PD is characterized by a series of motor and non-motor symptoms. However, the association between cognitive impairment and clinical features of motor and non-motor symptoms in PD is inconsistent, there- fore, it needs to be further studied. Methods: 394 PD patients were recruited and assessed by MDS-UPDRS and a battery of neuropsycho- logical tests. Transcranial sonography (TCS) was used to detect the substantia nigra echogenic areas (SNL). Results: Nearly 9.4% (n¼37) of PD reported cognitive impairment evalu- ated by MMSE. Patients with cog- nitive impairment (PD-CI) had older age (p¼0.028), lower education level (p¼0.000), longer disease dura- tion (P¼0.011), higher H&Y stage (p¼0.004), higher scores in MDS-UPDRS-III (p¼0.001), MDS-UPDRS-total (p¼0.000), NMSs (p¼0.000), PDSS (p¼0.042), HAMD17 (p¼0.005), HAMA (p¼0.000), PDQ-39 (p¼0.000), BPI (p¼0.018), SS-16 (p¼0.006), SCOPA-AUT (p¼0.001), ESS (p¼0.022). With respect to the subdivision of the UPDRS III scores, speech/facial expression, rigidity, bradykinesia and gait/posture exhibited higher scores in PD-CI group (p< 0.01). In the further analysis of NMSs, excessive daytime sleepiness, anxiety, hallucination, concentration prob- lems, excessive saliva, urinary fre- quency, were more common in PD-CI patients. Spearman rank correlation revealed that MMSE score was associated with age (r ¼ -0.145, P¼0.004), education (r ¼ -0.448, P¼0.000), H&Y stage (r ¼ -0.225, P¼0.000), speech/ facial expression (r ¼ -0.231, P¼0.000), rigidity (r ¼ -0.236, P¼0.000), bradykinesia (r ¼ -0.236, P¼0.000), gait/posture (r ¼ -0.249, P¼0.000), excessive daytime sleepiness (r ¼ -0.128, P¼0.011), anxiety (r ¼ -0.131, P¼0.009), concentration problems (r ¼ -0.103, P¼0.042), excessive saliva (r ¼ -0.208, P¼0.000), urinary frequency (r ¼ -0.148, P¼0.003), nocturia (r ¼ -0.171, P¼0.001). Conclusions: Cognitive impairment was associated with age, education, H&Y stage, speech/facial expres- sion, rigidity, bradykinesia, gait/posture, excessive daytime sleepiness, anxiety, concentration problems, excessive saliva, urinary frequency, nocturia, unexplained pains and hyposmia. P-042 RHO KINASE INHIBITORS - A GROWING NEUROPROTECTIVE THERAPEUTIC PARADIGM V. Abbhi, P. Piplani. University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India Objectives: Protein kinases are involved in a number of vital cellular signal transductions. They have strict mechanism of activation and inactivation to prevent spurious cellular signaling; overactivity can cause a number of diseases and necessitates their selective inhibition as a possible treat- ment option. Growing evidences implicate the involvement of Rho kinase pathway in various neurodegenerative diseases like Alzheimer’s (AD) and glaucoma. Rho kinase inhibitors have been known to accelerate axon regeneration in these neurological disorders. They also improve the cell survival by protecting them against the oxida- tive damage. The present study aims to design and synthesize novel Rho kinase in- hibitors which may be useful for the treatment of neurodegenerative diseases. Method: Mixture of o-phenylenediamine and cyanogen bromide was stirred at room temperature in water and basified with sodium hydroxide to afford 2-aminobenzimidazole. It was further refluxed with various substituted phenyl isocyanates in tetrahydrofuran to yield respective benzimidazole derivatives. These compounds were docked at the enzy- matic pocket to see the possible interactions with the kinase. The partition coefficient was calculated for the synthesized compounds using Shake flask method. The antioxidant effect was determined using a DPPH model. The enzyme-based assay was carried out to es- tablish the Rho kinase inhibitory activity of the synthesized molecules. Results: The structure of the synthesized compounds was ascertained using various spectral techniques and elemental analysis. They were found to be lipophilic in nature and elicited a considerable antioxidant effect as compared to the standard drug, fasudil. The compounds showed optimum interactions with the kinase and an appreciable Rho kinase inhibitory activity. Conclusion: The pharmacological and the enzymatic studies have sug- gested that the compounds inhibit the ROCK (Rho kinase) pathway and may be used as neuroprotective therapeutic paradigm for treatment of various diseases like AD or glaucoma which are closely associated to each other. P-043 COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE K. Narkulova 1 , B. Abdullaev 2 , A. Kostyunina 1 . 1 Neurology, Tashkent Pediatrics Medical Institute, Tashkent, Uzbekistan; 2 Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan Introduction: Cognitive impairment (CI) is a common non-motor complication of Parkinson’s disease (PD). It is associated with important disability for patients and burden for house nurses. Many people with PD are to find that they feel distracted and disorganized, or have difficulty planning, thinking and carrying through tasks. Purpose: The cognitive disorders on society is high and escalating. Epidemiological studies have indi- cated rising prevalence rates with many other diseases having cognitive disorders as associated. However, the neurocognitive regulation of Parkinson’s disease (PD) is not fully studied. Materials and methods: For this study, we chose 8 patients with PD and mean age was 57±3.6. 5 patients were men and 3 were women. All pa- tients were diagnosed according to clinical and instrumental-lab- oratory analyses (Cardinal features, micrographia, CT/MRI scan). Mini-Mental State Examination (MMSE) and Montreal scale assessment of cognitive func- tions (MoCA), the Saint Louis University Mental Status Examination (SLUMS) were utilized. All patients take both L-Dopa and Bromocryptine (or Pergolide) for many years. Results: Patients were excluded if MMSE scores were < 24, suggesting dementia. MMSE showed that in 7 patients, overall result was 25.4±0.9; in MoCA, it was 25.2±0.5, and for SLUMS, it was 23.8±0.4. In all patients have language difficulty; in 5 have slowness of memory. It was not difficult to define decreased attention and concentration, word-finding disturbances. Conclusion: CI in PD is frequent, occurring in 25% of PD patients which was reported by Goldman et al. The results can potentially serve as a cognition index for determination of levels of mild CI across PD. Study describes the neural correlates involved in the neurocognitive regulation of PD. This understanding would help to improve the care for PD patients in both early and late stages. Moreover, cognitive impair- ment identified patients must undertake certain therapy such as medications rivastigmine, donezepile or galantamine. P-044 NEUROPSYCHIATRIC DISORDERS IN IDIOPATHIC PARKINSON’S DISEASE S. Halder , M.U. Kulsum, B. Mondal, A. Dutt, S.S. Anand, H. Kumar. Neurology, Institute of Neurosciences Kolkata, Kolkata, India Introduction: Psychiatric and behavioral symptom associated with Par- kinson’s disease (PD) is a frequently encountered problem in PD patients. By reason of inadequate accessibility of reports in this ethnic popula- tion; we intended to assess the frequency and determinants of PD associated psychiatric disorders. Objective: 1. To study prevalence of various psychiatric disorders in patients with PD. 2. To compare the prevalence of psychiatric disorders in Tremor dominant (TD) variant of PD with that in postural instability gait difficulty (PIGD) variants of PD. Abstracts / Parkinsonism and Related Disorders 46 (2018) e47ee51 e48